Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2Rb wild-type and knock-down in breast cancer cell lines

Fig. 2

Sequential administration of Rib and Eve induced cytotoxicity in Rb WT and KD MCF-7 cells. Cell viability was determined by MTT assay. Rb WT and KD MCF-7 cells were treated with different dosing schedule: a-c Rib 3 days followed by Eve 2 days and b-d Eve 3 days followed by Rib 2 days with different concentrations (5, 10 and 20 μg/mL). Data shown are expressed as mean ± SE of three separate experiments. *p < 0.05 Sequential schedule vs single drug

Back to article page